224 related articles for article (PubMed ID: 32039379)
21. Structural basis of sodium-dependent bile salt uptake into the liver.
Goutam K; Ielasi FS; Pardon E; Steyaert J; Reyes N
Nature; 2022 Jun; 606(7916):1015-1020. PubMed ID: 35545671
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
[TBL] [Abstract][Full Text] [Related]
23. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
Yan H; Li W
Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
[TBL] [Abstract][Full Text] [Related]
24. Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Glebe D; Geyer J
Sci Rep; 2020 Dec; 10(1):21772. PubMed ID: 33303817
[TBL] [Abstract][Full Text] [Related]
25. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
Kirstgen M; Müller SF; Lowjaga KAAT; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Baringhaus KH; Krieg R; Glebe D; Geyer J
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452354
[TBL] [Abstract][Full Text] [Related]
26. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
Li W; Urban S
J Hepatol; 2016 Apr; 64(1 Suppl):S32-S40. PubMed ID: 27084034
[TBL] [Abstract][Full Text] [Related]
27. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
[TBL] [Abstract][Full Text] [Related]
28. Mutational Analysis of the GXXXG/A Motifs in the Human Na
Palatini M; Müller SF; Lowjaga KAAT; Noppes S; Alber J; Lehmann F; Goldmann N; Glebe D; Geyer J
Front Mol Biosci; 2021; 8():699443. PubMed ID: 34239896
[TBL] [Abstract][Full Text] [Related]
29. Blocking Sodium-Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice.
Roscam Abbing RLP; Slijepcevic D; Donkers JM; Havinga R; Duijst S; Paulusma CC; Kuiper J; Kuipers F; Groen AK; Oude Elferink RPJ; van de Graaf SFJ
Hepatology; 2020 Jan; 71(1):247-258. PubMed ID: 31136002
[TBL] [Abstract][Full Text] [Related]
30. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
31. Na
Slijepcevic D; Roscam Abbing RLP; Fuchs CD; Haazen LCM; Beuers U; Trauner M; Oude Elferink RPJ; van de Graaf SFJ
Hepatology; 2018 Sep; 68(3):1057-1069. PubMed ID: 29572910
[TBL] [Abstract][Full Text] [Related]
32. Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function
Saran C; Ho H; Honkakoski P; Brouwer KLR
Front Pharmacol; 2023; 14():1147495. PubMed ID: 37033614
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
Zhao K; Liu S; Chen Y; Yao Y; Zhou M; Yuan Y; Wang Y; Pei R; Chen J; Hu X; Zhou Y; Zhao H; Lu M; Wu C; Chen X
Emerg Microbes Infect; 2018 Nov; 7(1):186. PubMed ID: 30459339
[TBL] [Abstract][Full Text] [Related]
34. The Lipid Raft Component Stomatin Interacts with the Na
Appelman MD; Robin MJD; Vogels EWM; Wolzak C; Vos WG; Vos HR; Van Es RM; Burgering BMT; Van de Graaf SFJ
Cells; 2020 Apr; 9(4):. PubMed ID: 32316189
[TBL] [Abstract][Full Text] [Related]
35. The hepatitis B virus receptor.
Li W
Annu Rev Cell Dev Biol; 2015; 31():125-47. PubMed ID: 26436705
[TBL] [Abstract][Full Text] [Related]
36. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.
Blank A; Eidam A; Haag M; Hohmann N; Burhenne J; Schwab M; van de Graaf S; Meyer MR; Maurer HH; Meier K; Weiss J; Bruckner T; Alexandrov A; Urban S; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2018 Feb; 103(2):341-348. PubMed ID: 28543042
[TBL] [Abstract][Full Text] [Related]
37. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
38. Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo.
He W; Cao Z; Mao F; Ren B; Li Y; Li D; Li H; Peng B; Yan H; Qi Y; Sun Y; Wang F; Sui J; Li W
J Virol; 2016 Oct; 90(19):8866-74. PubMed ID: 27466423
[TBL] [Abstract][Full Text] [Related]
39. Ergosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor.
Chiou WC; Lyu YS; Hsia TL; Chen JC; Lin LC; Chang MF; Hsu MS; Huang C
Biomed Pharmacother; 2024 Jan; 170():116077. PubMed ID: 38154274
[TBL] [Abstract][Full Text] [Related]
40. Decreased Na+-dependent taurocholate uptake and low expression of the sinusoidal Na+-taurocholate cotransporting protein (Ntcp) in livers of mdr2 P-glycoprotein-deficient mice.
Koopen NR; Wolters H; Voshol P; Stieger B; Vonk RJ; Meier PJ; Kuipers F; Hagenbuch B
J Hepatol; 1999 Jan; 30(1):14-21. PubMed ID: 9927146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
